Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena Pharmaceuticals has announced that Taisho Pharmaceutical has started a Phase I clinical trial of a drug candidate under a GPCR-focused partnership with Arena to develop compounds to treat psychiatric disorders.
Subscribe to our email newsletter
The drug candidate is a novel oral compound intended for the treatment of a common psychiatric disorder. Under an amended agreement with Taisho, which was initially executed in May of 2000 to research a number of different GPCR targets of interest to Taisho, Taisho is responsible for development and commercialization of the drug candidate. Arena is entitled to a low single digit royalty on any product revenues received by Taisho from the sale of the drug candidate.
Jack Lief, Arena’s president and CEO, said: “We are very happy to see our long-standing partner, Taisho, effectively continue its efforts under our existing collaboration. We look forward to the Phase I results and the continued progress of this program.”